Evidence map›Paper›PMID 32048158›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment.

A Bonaventura, F Grossi, F Carbone, A Vecchié, S Minetti, N Bardi, E Elia, A M Ansaldo, D Ferrara, E Rijavec and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

A BonaventuraFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy. aldo.bonaventura@vcuhealth.org.ORCID http://orcid.org/0000-0002-4747-5535
F GrossiFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Medical Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-8412-3136
F CarboneFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0003-2957-4078
A VecchiéFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0003-0410-5996
S MinettiFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
N BardiFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
E EliaFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
A M AnsaldoFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
D FerraraFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.
E RijavecIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.
M G Dal BelloIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.
G RossiIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0001-8432-5408
F BielloAzienda Ospedaliero-Universitaria Maggiore Della Carità, Novara, Italy.
M TagliamentoIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.
A AlamaIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0002-9726-201X
S CocoIRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0002-5296-4325
P SpallarossaCardiovascular Diseases Unit, IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular Network, Genoa, Italy.
F DallegriFirst Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, viale Benedetto XV 6, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0001-9537-4547
C GenovaIRCCS Ospedale Policlinico San Martino Genova-Italian Cardiovascular Network, Largo R. Benzi 10, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0003-3690-8582
F MontecuccoIRCCS Ospedale Policlinico San Martino Genova-Italian Cardiovascular Network, Largo R. Benzi 10, 16132, Genoa, Italy.ORCID http://orcid.org/0000-0003-0823-8729
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITVirginia Commonwealth University · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Sassari · IT

Funding

Fondazione Cassa di Risparmio di Genova e Imperia #2754291Ministero della Salute Rete CardiovascolareMinistero della Salute Ricerca Corrente
6 · The paper itself

Abstract

purposeSince the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS. METHODS/PATIENTS: From a cohort of 78 patients with advanced NSCLC enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 43 patients have been considered for this sub-analysis because of the availability of samples. Before and during nivolumab administration, clinical information and blood samples were collected and resistin, matrix metalloproteinase (MMP)-8, MMP-9, and myeloperoxidase were evaluated by enzyme-linked immunosorbent assay (ELISA).

resultsMedian age was 71 with a prevalence of males and former smokers. Median resistin levels presented a peak at cycle 2 and then dropped down until the last cycle. Resistin correlated with all neutrophil degranulation products at cycle 1 (except for MMP-9) and at cycle 2 as well as with white blood cells and neutrophils. By a ROC curve analysis, a resistin value at cycle 2 of 19 ng/mL was tested as the best cut-off point for OS. Kaplan-Meier analysis demonstrated that patients above the resistin cut-off experienced a reduced OS (median OS 242.5 vs. 470 days, p = 0.0073), as confirmed by Cox proportional hazards regression analysis.

conclusionsResistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC.

Indexed as

AgedAntineoplastic Agents, ImmunologicalBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedNeutrophilsNivolumabPrognosisProspective StudiesResistinSurvival RateTreatment OutcomeAntineoplastic Agents, ImmunologicalBiomarkers, TumorNivolumabResistinImmunotherapyLung cancerNeutrophilsNivolumabNSCLCResistin

Identifiers

PMID32048158
OpenAlexW3006259047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.